Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial

PaperCitations, authors & open-access status

Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 47 citations, 2024 year and closed oa status.

47
Citations
2024
Year
closed
OA Status

Related on ScholarIQ

Yiming Zhao
Author
Journal of Clinical Oncology
Journal
HER2/EGFR in Cancer Research
Topic
HER2/EGFR in Cancer Research
Topic
Advanced Breast Cancer Therapies
Topic
Colorectal Cancer Treatments and Studies
Topic
470M+ articles · free account